Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

التفاصيل البيبلوغرافية
العنوان: Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study
المؤلفون: Hörsch, Dieter, Anthony, Lowell, Gross, David J., Valle, Juan, Welin, Staffan, Benavent, Marta, Caplin, Martyn, Pavel, Marianne, Bergsland, Emily, Öberg, Kjell, 1946, Kassler-Taub, Kenneth B., Binder, Polina, Banks, Phillip, Lapuerta, Pablo, Kulke, Matthew H.
المصدر: Neuroendocrinology. 112(3):298-309
مصطلحات موضوعية: Telotristat ethyl, Carcinoid syndrome, Diarrhea, Safety and tolerability, Quality of life
الوصف: Introduction: Telotristat ethyl is indicated for use in combination with somatostatin analogs (SSAs) to treat carcinoid syndrome (CS) diarrhea uncontrolled by SSAs alone in adults, but long-term safety and efficacy data beyond 48 weeks are needed.Objectives: The aims of the study were to evaluate the long-term safety and tolerability of telotristat ethyl and its effect on quality of life (QOL) in patients with CS.Methods: In this phase 3, nonrandomized, multicenter, open-label, long-term extension study (TELEPATH), patients who participated in phase 2 or 3 trials of telotristat ethyl continued treatment at their present dose level (250 or 500 mg thrice daily) for 84 weeks. Safety and tolerability, the primary endpoint, were assessed by monitoring adverse events (AEs), serious AEs, AEs of special interest (AESIs; including liver-related AEs, depression, and gastrointestinal AEs), and deaths. The secondary objective was to evaluate changes in patients’ QOL using validated cancer questionnaires and a subjective global assessment of CS symptoms.Results: In 124 patients exposed to telotristat ethyl for a mean of 102.6 ± 53.2 weeks, the type and frequency of AEs were consistent with those reported in previous trials. The occurrence of AESIs was not related to dosage or duration of therapy. Most AEs were mild to moderate in severity, and no deaths were related to telotristat ethyl. QOL scores remained stable, and the majority of patients reported adequate symptom relief throughout the study.Conclusions: Safety results of TELEPATH support the long-term use of telotristat ethyl in patients with CS diarrhea. Telotristat ethyl was well-tolerated and associated with sustained improvement in QOL scores (NCT02026063).
وصف الملف: electronic
الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-502260Test
https://doi.org/10.1159/000516958Test
https://uu.diva-portal.org/smash/get/diva2:1759133/FULLTEXT01.pdfTest
قاعدة البيانات: SwePub
الوصف
تدمد:00283835
14230194
DOI:10.1159/000516958